0001209191-22-057985.txt : 20221118 0001209191-22-057985.hdr.sgml : 20221118 20221118184204 ACCESSION NUMBER: 0001209191-22-057985 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221116 FILED AS OF DATE: 20221118 DATE AS OF CHANGE: 20221118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kumar Neil CENTRAL INDEX KEY: 0001742485 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 221403153 MAIL ADDRESS: STREET 1: C/O EIDOS THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-16 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001742485 Kumar Neil C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 1 1 0 0 CEO and President Common Stock 2022-11-16 4 M 0 68706 A 4881903 D Common Stock 2022-11-16 4 F 0 34066 9.64 D 4847837 D Common Stock 2022-11-17 4 S 0 34640 9.3997 D 4813197 D Common Stock 1612722 I See Footnote Common Stock 1195686 I See Footnote Restricted Stock Units 2022-11-16 4 M 0 5130 0.00 D Common Stock 5130 30776 D Restricted Stock Units 2022-11-16 4 M 0 2394 0.00 D Common Stock 2394 21548 D Restricted Stock Units 2022-11-16 4 M 0 61182 0.00 D Common Stock 61182 305910 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 68,706 shares of Common Stock underlying the Reporting Person's RSUs. Represents the weighted average sale price of the shares sold from $9.16 to $9.65 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein. The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date. The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date. /s/ Brian C. Stephenson, Attorney-in-Fact 2022-11-18